Mark Sullivan, Chief Legal Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), filed a Form 4 on August 12, 2026, disclosing the acquisition of 62,500 common shares at $0.00 through the vesting of performance share units.

Key Highlights

  • Transaction date: August 12, 2026, with 62,500 common shares acquired via transaction code "A" at a price of $0.00.
  • Performance share units: The shares represent the second tranche of performance share units granted effective March 12, 2025.
  • Vesting condition: Shares remain subject to vesting based on the reporting person's continued employment through March 12, 2028.
  • Milestone-based: Each performance share unit represented a contingent right to receive one common share based on the achievement of certain clinical and regulatory milestones.
  • Resulting ownership: Following the transaction, Sullivan beneficially owns 383,071 common shares directly.

Mark Sullivan's Performance Share Unit Transaction at Definium Therapeutics

According to the filing, Mark Sullivan, serving as Chief Legal Officer of Definium Therapeutics, Inc., reported the acquisition of 62,500 common shares on August 12, 2026. The transaction was recorded under code "A" (acquired) at a price of $0.00, reflecting the non-cash nature of the award. The filing identifies the issuer as Definium Therapeutics, Inc., trading on NASDAQ:DFTX.

The filing discloses that the 62,500 shares "represent the second tranche of performance share units granted effective March 12, 2025." According to the explanation of responses, the shares "remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028." The filing further states that each performance share unit "represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."

Following the reported transaction, the filing states that Sullivan directly and beneficially owns 383,071 common shares. No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was signed by Mark Sullivan on August 12, 2026.

What Was Disclosed

Definium Therapeutics Chief Legal Officer Mark Sullivan reported the acquisition of 62,500 common shares on August 12, 2026, at $0.00, representing the second tranche of performance share units originally granted March 12, 2025, with vesting tied to continued employment and clinical and regulatory milestones.